Millennium Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Millennium Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$5.93M	–	7941
2022 Q1	$5.93M	Buy	50,000 +40,000	+400%	+$4.99M	﹤0.01%	2746
2021 Q4	$1.38M	Buy	+10,000	New	+$1.27M	﹤0.01%	4106
2021 Q3	–	Sell	-10,000	Closed	-$971K	–	7685
2021 Q2	$971K	Buy	+10,000	New	+$812K	﹤0.01%	4695
2021 Q1	–	Sell	-8,500	Closed	-$729K	–	6913
2020 Q4	$729K	Buy	+8,500	New	+$720K	﹤0.01%	3940
2020 Q2	–	Sell	-39,400	Closed	-$1.34M	–	4901
2020 Q1	$1.34M	Buy	+39,400	New	+$1.8M	﹤0.01%	2285
2018 Q3	–	Sell	-19,200	Closed	-$759K	–	4584
2018 Q2	$759K	Buy	+19,200	New	+$609K	﹤0.01%	2977

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Millennium Management's BHVN Position: Q3 2022 in Review

Millennium Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 691,902 shares — an estimated $101M sold.

Millennium Management first reported a position in BHVN in Q4 2017 and held it in 17 quarters. The position peaked at $101M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Millennium Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 691,902 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $101M.
Millennium Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 17 quarters.
Millennium Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $101M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.